We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Oral Rigosertib for Squamous Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01807546
Recruitment Status : Completed
First Posted : March 8, 2013
Last Update Posted : June 26, 2017
Information provided by (Responsible Party):
Onconova Therapeutics, Inc.

Brief Summary:

The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following treatment with the investigational drug, rigosertib sodium (ON 01910.Na). A secondary objective is to determine if treatment with rigosertib causes any side effects.

Rigosertib is an investigational drug, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) to treat any diseases. We are studying rigosertib as a new anticancer drug. Tests that we have done in the laboratory suggest that rigosertib works by blocking cell division in cancer cells and causing them to die.

Condition or disease Intervention/treatment Phase
Head and Neck Squamous Cell Carcinoma Anal Squamous Cell Carcinoma Lung Squamous Cell Carcinoma Cervical Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma Skin Squamous Cell Carcinoma Penile Squamous Cell Carcinoma Drug: rigosertib Phase 2

Detailed Description:

This will be a multicenter, Phase II study to evaluate the safety and efficacy of oral rigosertib in patients with relapsed or metastatic squamous cell carinoma (SCC) who previously received platinum-based chemotherapy and/or chemo-radiation therapy.

Only patients with head and neck squamous cell carinoma (HNSCC), non-small cell lung SCC, skin SCC, cervical SCC, penile SCC, anal SCC or esophageal SCC will be enrolled in the study.

Patients will be administered rigosertib capsules at a dose of 560 mg BID on days 1 to 14 of a 21-day cycle. Patients will be enrolled in 2 cohorts based on HPV test results:

  • Cohort 1 will include up to 40 patients with human papillomavirus (HPV)-positive SCC, of which approximately 30 patients will have HNSCC, and approximately 10 patients with SCC of another origin (eg, cervix, anal, penile);
  • Cohort 2 will include up to 40 patients with HPV-negative SCC, of which approximately 30 patients will have HNSCC, and approximately 10 patients with SCC of another origin (eg, lung, skin, esophageal).

Patients will be evaluated for progression after completing 3 cycles of therapy and every 3 cycles thereafter. Patients with stable disease (SD) or better, based on revised Response Criteria in Solid Tumors (mRECIST) 1.1, will receive repeated cycles of treatment on a 21-day cycle schedule until disease progression, development of unacceptable toxicity, or withdrawal of consent. Patients with progressive disease (PD) but who, in the opinion of the Investigator, appear to be deriving clinical benefit, may continue on study with a planned disease reassessment after one further cycle of therapy. Should the patient have SD or PR at this reassessment, s/he may continue on study, with subsequent reassessments every 3 cycles.

Following discontinuation of rigosertib treatment, patients' mortality status will be assessed every 3 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma
Study Start Date : March 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : April 2016

Arm Intervention/treatment
Experimental: rigosertib
Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
Drug: rigosertib
Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
Other Name: ON 01910.Na

Primary Outcome Measures :
  1. Overall response rate [ Time Frame: Baseline to 9 weeks after start of rigosertib treatment and every 9 weeks thereafter, up to 2 years. ]
    Outcome is defined as the number of patients with Complete Response (CR) or Partial Response (PR) per revised Response Evaluation Criteria In Solid Tumors (RECIST 1.1). Complete response (CR) is defined as disappearance of all target lesions. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: Date of signing ICF to date of death, or date last known to be alive up to 2 years after discontinuation of rigosertib treatment. ]
    At the time of analysis, the outcome measure will be number of days between the date the patient is enrolled in the study and the date the patient dies or date the patient is last known to be alive, up to 2 years following discontinuation of rigosertib treatment.

  2. Progression free survival (PFS), [ Time Frame: 9 weeks, 18 weeks, and 27 weeks and every 9 weeks thereafter, up to 2 years after patient enrolled in the study. ]
    At the time of analysis, the outcome measure will be number of days between the date the patient is enrolled in the study and the date that progressive disease (PD) is documented per revised Response Evaluation Criteria In Solid Tumors (RECIST 1.1).

  3. Concentration of rigosertib in plasma [ Time Frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 2 Day 14 at 0, 0.5, 1, 1.5, 2, and 6 hours after the first dose of the day. ]
    The concentration (expressed as microgram rigosertib per mL plasma and/or nanogram rigosertib per mL plasma) of rigosertib in plasma will be determined by a validated high performance liquid chromatography (HPLC) method.

  4. Levels of Biomarkers [ Time Frame: Baseline ( study before drug administration) and Cycle 1, Day 14. ]
    Genetic and protein profiling will be conducted in blood (collected at Baseline before study drug administration) and in core biopsy or fine needle aspirate tumor samples (collected at Baseline before study drug administration and at Cycle 1 Day 14).

  5. Number of Adverse Events [ Time Frame: From signing of Informed Consent Form until 30 days after last dose of study drug. ]
    All Adverse Events reported by the patient or observed by the Investigator or study site personnel will be recorded. An adverse event is defined as any unfavorable or unintended sign, symptom, or disease that appears or worsens in a patient during the period of observation in a clinical study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed SCC; only patients with HNSCC, non-small cell lung SCC, skin SCC, cervical SCC, penile SCC, anal SCC, or esophageal SCC;
  2. For patients with HNSCC only, HPV status must be assessed by in situ hybridization (ISH) and/or p16 immunohistochemistry (IHC) according to local standards;
  3. For patients with HNSCC only, HPV status must be assessed by in situ hybridization (ISH) and/or p16 immunohistochemistry (IHC) according to local standards. For all other patients with SCC originating in tissues other than the head and neck, attempts should be made to obtain HPV status;
  4. Incurable, non-resectable, locally-advanced/relapsed and/or distant metastatic disease after no more than 3 prior treatment regimens, one of which must be platinum-based chemotherapy;
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
  6. Life expectancy of at least 3 months;
  7. Measurable disease according to RECIST version 1.1;
  8. Ability to swallow entire capsules;
  9. Adequate hematologic function;
  10. Adequate hepatic function;
  11. Adequate renal function;
  12. Adequate contraceptive regimens for female and male patients;
  13. Female patients with reproductive potential must have a negative urine or serum pregnancy test;
  14. Ability to understand the nature of the study and any hazards of study participation, to communicate satisfactorily with the Investigator, and to follow the requirements of the entire protocol;
  15. Willingness to adhere to the prohibitions and restrictions specified in this protocol;
  16. The patient must sign an informed consent form (ICF).

Exclusion Criteria:

  1. Chemotherapy or any potentially myelosuppressive treatment within 3 weeks prior to enrollment (6 weeks are required for nitrosoureas or mitomycin C);
  2. Radiotherapy to >25% of the hematopoietic active bone marrow within 4 weeks prior to enrollment;
  3. Systemic administration of corticosteroids within the past 4 weeks prior to enrollment;
  4. Prior therapy with a phosphatidylinositol 3-kinase (PI3K), Akt or mammalian target of rapamycin (mTOR) inhibitor;
  5. Any other investigational agent or chemotherapy, radiotherapy, or immunotherapy within 4 weeks of enrollment;
  6. Major surgery within 3 weeks of enrollment or major surgery without full recovery;
  7. Residual clinical signs and symptoms which have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) version 4 Grade 1 severity level or below before enrollment, except for alopecia, stable residual neuropathy, and residual hand/foot syndrome;
  8. Known brain metastases, except for those that have been removed or irradiated and have no current clinical impact at the time of enrollment; a computed tomography (CT) scan or magnetic resonance imaging (MRI) of the brain should be obtained in patients with symptoms suggestive of brain metastases;
  9. Ascites requiring active medical management, including paracentesis;
  10. Serum sodium less than 130 mEq/L or conditions that may predispose patients to hyponatremia (eg, previous syndrome of inappropriate antidiuretic hormone hypersecretion [syndrome of inappropriate antidiuretic hormone secretion (SIADH)], chronic diuretic use, etc.);
  11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, bleeding, symptomatic congestive heart failure, unstable angina pectoris, and cardiac arrhythmia;
  12. Uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg;
  13. New onset of seizures within 3 months prior to enrollment, or poorly controlled seizures;
  14. Psychiatric illness/social situations that would limit the patient's ability to tolerate and/or comply with study requirements;
  15. History of allergic reactions attributed to compounds of similar chemical or biologic composition to rigosertib;
  16. Female patients who are pregnant or lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01807546

Layout table for location information
United States, California
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
Stanford Cancer Institute
Stanford, California, United States, 94305
United States, Colorado
University of Colorado School of Medicine
Aurora, Colorado, United States, 80045
Denver VA Medical Center-ECHCS
Denver, Colorado, United States, 80220
United States, Michigan
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109
United States, New Jersey
Veterans Administration New Jersey Health Care System
East Orange, New Jersey, United States, 07018
United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10029
Montefiore Medical Center
The Bronx, New York, United States, 10467
United States, Ohio
Ohio State University, James Cancer Hospital
Columbus, Ohio, United States, 43210
United States, Pennsylvania
University of Pennslvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Mary Crowley Cancer Research Center
Dallas, Texas, United States, 75201
United States, Virginia
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States, 22031
Blue Ridge Cancer Care
Salem, Virginia, United States, 24153
Sponsors and Collaborators
Onconova Therapeutics, Inc.
Layout table for investigator information
Study Director: Michael Kurman, MD Onconova Therapeutics, Inc.
Additional Information:
Publications of Results:
Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.

Other Publications:
Layout table for additonal information
Responsible Party: Onconova Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01807546    
Other Study ID Numbers: Onconova 09-09
COMIRB 13-0116 ( Other Identifier: University of Colorado School of Medicine )
First Posted: March 8, 2013    Key Record Dates
Last Update Posted: June 26, 2017
Last Verified: June 2017
Keywords provided by Onconova Therapeutics, Inc.:
Head and neck cancer
Squamous cell carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Esophageal Squamous Cell Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
ON 01910
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action